204 related articles for article (PubMed ID: 29322659)
1. Integrating dose estimation into a decision-making framework for model-based drug development.
Dunyak J; Mitchell P; Hamrén B; Helmlinger G; Matcham J; Stanski D; Al-Huniti N
Pharm Stat; 2018 Mar; 17(2):155-168. PubMed ID: 29322659
[TBL] [Abstract][Full Text] [Related]
2. Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation.
Al-Huniti N; Xu H; Zhou D; Aksenov S; Fox R; Bui KH
CPT Pharmacometrics Syst Pharmacol; 2017 Oct; 6(10):705-711. PubMed ID: 28782266
[TBL] [Abstract][Full Text] [Related]
3. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K
Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
5. Better decision making in drug development through adoption of formal prior elicitation.
Dallow N; Best N; Montague TH
Pharm Stat; 2018 Jul; 17(4):301-316. PubMed ID: 29603614
[TBL] [Abstract][Full Text] [Related]
6. Naloxegol increases frequency of bowel movements and combats inadequate response to laxatives.
Holzer P
Evid Based Med; 2015 Feb; 20(1):5. PubMed ID: 25209526
[No Abstract] [Full Text] [Related]
7. Naloxegol for managing opioid-induced constipation.
Shelton KN; Clements JN
JAAPA; 2017 Sep; 30(9):51-53. PubMed ID: 28858018
[TBL] [Abstract][Full Text] [Related]
8. Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development.
Crisp A; Miller S; Thompson D; Best N
Pharm Stat; 2018 Jul; 17(4):317-328. PubMed ID: 29635777
[TBL] [Abstract][Full Text] [Related]
9. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
[TBL] [Abstract][Full Text] [Related]
10. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.
Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D
Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715
[TBL] [Abstract][Full Text] [Related]
12. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.
Bui K; Birmingham B; Diva U; Berger B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):420-427. PubMed ID: 28127938
[TBL] [Abstract][Full Text] [Related]
13. The impact of naloxegol on anal sphincter function - Using a human experimental model of opioid-induced bowel dysfunction.
Grønlund D; Poulsen JL; Krogh K; Brock C; Liao D; Gregersen H; Drewes AM; Olesen AE
Eur J Pharm Sci; 2018 May; 117():187-192. PubMed ID: 29432808
[TBL] [Abstract][Full Text] [Related]
14. How modeling and simulation have enhanced decision making in new drug development.
Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
[TBL] [Abstract][Full Text] [Related]
15. Optimal planning of phase II/III programs for clinical trials with multiple endpoints.
Kieser M; Kirchner M; Dölger E; Götte H
Pharm Stat; 2018 Sep; 17(5):437-457. PubMed ID: 29700949
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.
Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):442-8. PubMed ID: 27137716
[TBL] [Abstract][Full Text] [Related]
17. Decision-making in early clinical drug development.
Frewer P; Mitchell P; Watkins C; Matcham J
Pharm Stat; 2016 May; 15(3):255-63. PubMed ID: 26991401
[TBL] [Abstract][Full Text] [Related]
18. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
19. Naloxegol for the treatment of opioid-induced constipation.
Tack J; Corsetti M
Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391
[TBL] [Abstract][Full Text] [Related]
20. Modelling and simulation in the pharmaceutical industry--some reflections.
Burman CF; Wiklund SJ
Pharm Stat; 2011; 10(6):508-16. PubMed ID: 22162317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
